Related Experiment Video
Updated: May 9, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Cancer-associated thrombosis: clinical presentation and survival.
1Department of Medicine, St Rita's Medical Center, Lima, OH, USA.
Cancer Management and Research
|August 9, 2013
Summary
Cancer patients frequently experience thromboembolic events, including venous and arterial thrombosis. Advanced cancer stage and atherosclerosis are key risk factors, with Caucasian ancestry showing higher genetic thrombophilia predisposition.
Area of Science:
- Oncology
- Hematology
- Vascular Medicine
Background:
- Thromboembolic events significantly contribute to morbidity and mortality in cancer patients.
- Clinical presentation of thrombosis in a community setting requires further clarification.
- Understanding cancer-related thrombosis is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the incidence of thrombosis in cancer patients.
- To identify risk factors, including genetic thrombophilia, associated with cancer-related thrombosis.
- To assess survival outcomes following thrombosis in cancer patients.
Main Methods:
- Retrospective review of clinical data from cancer patients at a regional cancer center.
- Analysis focused on cancer-related thrombosis, defined as occurring 3 months before or any time after cancer diagnosis.
- Inclusion of patients with histologically confirmed cancer.
Main Results:
- 16.4% of cancer patients developed thrombosis; 14.4% had cancer-related thrombosis.
- Venous thrombosis (12.3%) was more common than arterial occlusion (1.5%).
- Advanced cancer stage and atherosclerosis predicted thrombosis; Caucasian ancestry linked to higher genetic thrombophilia.
Conclusions:
- Arterial occlusion, alongside venous thrombosis, is common in cancer patients, particularly those of Caucasian ancestry.
- Genetic predisposition may play a role in cancer-related arterial and venous thrombosis.
- Thrombosis occurring around the time of cancer diagnosis is associated with the worst survival outcomes.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...